Medpace Holdings Inc vs Teucrium Wheat Fund — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Teucrium Wheat Fund trades at $24.49. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals.
| MEDP | WEAT | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $620.59 | $26.00 |
52-Week Low | $393.42 | $19.88 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
WEAT (Teucrium Wheat Fund) trades at $24.36, up 1.46% over the past day, with a bullish technical signal driven by moving averages. Recent performance includes a 9.9% gain over the past month and a 25% year-to-date increase as of Zacks Investment Research on July 21, 2026. The USDA reduced its 2026 U.S. wheat production outlook to 1.56 billion bushels on May 12, 2026, influencing commodity-driven volatility.
The outlook remains positive due to strong momentum and inflation hedging appeal, but risks include agricultural supply shocks and macroeconomic pressures. Investors should weigh the fund's exposure to wheat price swings against potential for continued commodity strength amid ongoing inflation concerns highlighted by ETF Trends as of June 2026.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →